Login to Your Account



Other News To Note


Tuesday, April 19, 2011
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said the FDA has accepted for review the company's biologics license application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD) and granted the company's request for priority review. The target date for an FDA decision on the VEGF Trap-Eye BLA is Aug. 20.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription